MorphoSys: A European Champion Crossing The Biopharma Rubicon
Insight Into Europe's Maturing Biopharma Market
Executive Summary
The Munich-based company is one of a handful of mature European biotechs poised to enter the big league. New CEO Jean-Paul Kress talks to In Vivo about the firm’s next generation antibody platform and why US expansion is crucial to its future.
You may also be interested in...
MorphoSys, After Its Commercial Debut, Looks To The Next Growth Phase
Interview: CEO Jean-Paul Kress talked to Scrip about the US launch of Monjuvi, commercial expansion and the aspiration to build a European biotech that can compete in the big leagues.
MorphoSys Chooses Incyte As Its Global Tafasitamab Partner
MorphoSys has chosen Incyte as its global partner for commercializing and further developing its lead asset, the Fc-engineered antibody tafasitamab that targets CD19.
Frontline Success Bolsters IO ‘Backbone’ Hopes For GSK’s Jemperli
GSK’s PD-1 inhibitor will not be able to make up much ground on Keytruda, but new studies suggest it is a match for the market-leading PD-1 inhibitors.